UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November, 2022
Commission File Number 001-39670
PURETECH HEALTH PLC
(Translation of registrant’s name into English)
6 Tide Street, Suite 400
Boston, Massachusetts 02210
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 10, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release noting that Christopher Viehbacher, Chair of the Company’s Board of Directors, has been appointed as President and Chief Executive Officer and a member of the Board of Directors of Biogen Inc. (Nasdaq: BIIB) effective November 14, 2022.
The press release issued by the Company is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PURETECH HEALTH PLC | ||||||
| Date: November 10, 2022 | By: | /s/ Daphne Zohar | ||||
| Name: | Daphne Zohar | |||||
| Title: | Chief Executive Officer | |||||
Exhibit 99.1
10 November 2022
PureTech Health plc
Director Declaration
Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company’s Board, has been appointed as President and Chief Executive Officer and a member of the Board of Biogen Inc. (Nasdaq: BIIB) with effect from November 14, 2022.
For further information please contact:
Bharatt Chowrira, PhD, JD, President and Chief Business, Finance and Operating Officer, member of the Board of Directors and Company Secretary: +1 617 482 2333